AX-024 is a T cell receptor (TCR) inhibitor. An orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC₅₀ = 1 nM). By modulating TCR signaling, the inhibitor prevents the development of psoriasis and asthma. Additionally, it exerts a long-lasting therapeutic effect in a model of autoimmune encephalomyelitis.